


TNF Counterbalances the Emergence of M2 Tumor Macrophages

Graphical Abstract



Authors

Franz Kratochvill, Geoffrey Neale, Jessica M. Haverkamp, ..., Michael A. Dyer, Joseph E. Qualls, Peter J. Murray

Correspondence

joseph.qualls@cchmc.org (J.E.Q.),
peter.murray@stjude.org (P.J.M.)

In Brief

Macrophage “polarization” in cancer involves heterogeneity between the M1 and M2 phenotypes. Most research and clinical data link M2 macrophages to pro-tumor activities. Kratochvill et al. show that TNF is essential for suppressing the number of M2 tumor macrophages. TNF also blocks IL-13 production, a pro-M2 cytokine, from activated eosinophils.

Highlights

- Tumor-associated macrophages (TAMs) are heterogeneous populations
- Loss of type I TNF receptor signaling causes a rise in M2 gene expression in TAMs
- TNF mediates a global anti-M2 pathway
- TNF suppresses IL-13 production from activated eosinophils

Accession Numbers

GSE59047
GSE68817



TNF Counterbalances the Emergence of M2 Tumor Macrophages

Franz Kratochvill,^{1,2} Geoffrey Neale,³ Jessica M. Haverkamp,^{1,2} Lee-Ann Van de Velde,^{1,2} Amber M. Smith,^{1,2} Daisuke Kawauchi,⁵ Justina McEvoy,^{4,6} Martine F. Roussel,⁵ Michael A. Dyer,⁴ Joseph E. Qualls,^{1,2,7,*} and Peter J. Murray^{1,2,*}

¹Department of Infectious Diseases

²Department of Immunology

³Hartwell Center for Biotechnology and Bioinformatics

⁴Department of Developmental Neurobiology

⁵Department of Tumor Cell Biology

St. Jude Children's Research Hospital, Memphis, TN 38105, USA

⁶Present address: University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, AZ 85742, USA

⁷Present address: Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA

*Correspondence: joseph.qualls@cchmc.org (J.E.Q.), peter.murray@stjude.org (P.J.M.)

<http://dx.doi.org/10.1016/j.celrep.2015.08.033>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

SUMMARY

Cancer can involve non-resolving, persistent inflammation where varying numbers of tumor-associated macrophages (TAMs) infiltrate and adopt different activation states between anti-tumor M1 and pro-tumor M2 phenotypes. Here, we resolve a cascade causing differential macrophage phenotypes in the tumor microenvironment. Reduction in TNF mRNA production or loss of type I TNF receptor signaling resulted in a striking pattern of enhanced M2 mRNA expression. M2 gene expression was driven in part by IL-13 from eosinophils co-recruited with inflammatory monocytes, a pathway that was suppressed by TNF. Our data define regulatory nodes within the tumor microenvironment that balance M1 and M2 populations. Our results show macrophage polarization in cancer is dynamic and dependent on the balance between TNF and IL-13, thus providing a strategy for manipulating TAMs.

INTRODUCTION

Macrophages are the most-abundant non-tumor-cell-populating cancers, and their numerical presence is correlated with poor clinical outcomes (Dannenmann et al., 2013; Gajewski et al., 2013; Galon et al., 2013; Zhang et al., 2012). The large numbers of macrophages in tumors raises a simple but unanswered question: what are macrophages doing in tumors? One possibility is macrophages seed tumors to repair tissue they detect as damaged. In cancer, malignant tissue looks like “self,” thereby escaping detection by immune cells. It therefore is hardly surprising macrophages are recruited to tumors if they are performing their normal “cleanup” functions. In doing so, macrophages may aid and abet an enemy within as proposed

by Dvorak in the “wounds that don't heal” model (Bissell and Hines, 2011; Dvorak, 1986).

Given that clinical and mouse model data frequently correlate macrophages with pro-tumor activities, several different tactics have been used to deplete or interfere with macrophage viability or recruitment including tyrosine kinase inhibitors or monoclonal antibodies targeting the colony-stimulating factor 1 receptor (CSF-1R), CD11b, or antibodies targeting CCL2, a chemokine for monocyte recruitment to tumors (Ahn et al., 2010; Bonapace et al., 2014; Pyonteck et al., 2013; Ries et al., 2014). However, the anti-macrophage activity of these drugs is not limited to macrophages in tumors. Macrophages are required for normal homeostatic functions and populate all tissues of the body. Therefore, gross targeting of monocytes and/or macrophages is likely to cause toxicities in tissues dependent on macrophages such as the gut, lungs, and heart (Epelman et al., 2014). Unanticipated side effects such as tumor rebound when drug therapy ceases have been reported (Bonapace et al., 2014). Macrophages are also critical for cell corpse disposal and tissue repair after chemotherapy, irradiation, or surgery. In these therapies, macrophages have time-dependent pro- and anti-tumor functions (De Palma and Lewis, 2013; Klug et al., 2013; Ma et al., 2013; Nakasone et al., 2012; Predina et al., 2013). Collectively, targeting specific pro-tumor macrophage functions rather than macrophages per se could be a valuable addition to standard-of-care therapies.

Macrophages and dendritic cells are “plastic” because their inflammatory mediator production is tailored for responsiveness to specific environmental cues (Murray and Wynn, 2011a; Wynn et al., 2013). Macrophages alter their effector and defense mechanisms across a spectrum between “M1” pro-inflammatory phenotypes—characterized by destructive anti-intracellular pathogen free radical and inflammatory cytokine production—and “M2” states—displayed by tissue-resident macrophages and macrophages encountering worms and fungi (Murray et al., 2014; Wynn et al., 2013). M2 macrophages express genes involved in tissue repair and resolution and have

immunosuppressive and immunoregulatory properties (Murray and Wynn, 2011b). In resolving inflammation, M1 macrophages can convert into M2 macrophages to restore tissue homeostasis and integrity during and after removal of the inciting entity (Wynn et al., 2013).

By contrast to resolving inflammation, chronic cancer-associated inflammation is a non-resolving response because of the persistence of malignant cells (Biswas and Mantovani, 2010; Nathan and Ding, 2010). An emerging body of clinical and experimental evidence links activated M1-like macrophages and cytotoxic CD8⁺ T cells to improved overall outcomes in cancer and cancer therapy, compared to poorer outcomes in cancers harboring numerous macrophages and low numbers of CD8⁺ T cells (Fridman et al., 2012; Gajewski et al., 2013; Predina et al., 2013). Macrophages with M2 gene expression are thought to be detrimental to anti-cancer therapies, and manipulation of their phenotype is considered key to the development of successful immunotherapies (De Palma and Lewis, 2013; Hanahan and Coussens, 2012; Qian and Pollard, 2010; Ruffell et al., 2012). Although actively debated, the mechanisms associated with macrophage polarization in cancer remain controversial. Most important is the absence of a coherent framework for understanding the signaling pathways controlling macrophage polarization and how polarization is regulated across time and space within a tumor. Here, we used a diverse range of tumor types, a systematic isolation strategy, and genetic platforms to dissect the signals regulating tumor-associated macrophage (TAM) polarization. Our results elucidate how mixtures of M1 and M2 can be simultaneously present and how these phenotypes change in tumors. We show M2 TAMs are enhanced by local amounts of IL-13 and antagonized by TNF. We found TNF is a key cytokine capable of blocking M2 gene expression in macrophages in general, and these effects of TNF on M2 genes are context dependent.

RESULTS

Macrophage Isolation Procedure from Diverse Tumor Types Does Not Alter Inflammatory Gene Expression

To gain insight into macrophage polarization in solid tumors, we compared macrophage infiltration in diverse genetic, anatomic, and orthotopic solid tumor models, including neuroblastomas, retinoblastomas, osteosarcomas, and the widely used implantable thymoma (EG7) model. Given the majority of TAMs originate from recruited CD11b⁺ blood monocytes (Cortez-Retamozo et al., 2012; Franklin et al., 2014; Movahedi et al., 2010; Shand et al., 2014), we optimized a TAM isolation procedure based on tissue digestion and CD11b⁺ magnetic bead isolation to capture the largest fraction of TAMs (Figure S1A). CD11b⁺ enrichment captures all monocytes and macrophages in the tumor microenvironment, in addition to neutrophils (discussed below), and avoids plastic enrichment steps (Biswas et al., 2006), which we found caused a decrease in the expression of numerous inflammatory mRNAs following TAM adherence (Figure S1B). To determine whether the isolation procedures themselves perturbed polarization-associated gene expression, we developed an in vitro 3D tumor-macrophage co-culture system where bone-marrow-derived macrophages are introduced into wells

containing a single tumor “sphere” and migrate inside (Figure S1C). We isolated the TAMs using the same tissue digestion and purification method described above and found few differences in M1 or M2 genes between the tumor or non-tumor macrophages. Importantly, gene expression linked to contaminating endotoxin such as TNF or IL6 was not increased by digestion (Figures S1D and S1E).

In CD11b⁺ TAMs, we detected high expression of TLR2 and CD14 mRNAs whereas mRNAs encoding other TLRs and the IL-1R had low or undetectable expression (Figure S2A). To further determine whether TAM isolation itself triggered inflammatory gene expression, we compared the CD11b⁺ fractions from TAMs (EG7) isolated from control or MyD88-deficient mice where all TLR and IL-1R signaling (except TLR3) is ablated. Because TLR3 was not expressed in TAMs (Figure S2A), the absence of MyD88 signaling should eliminate TAM TLR/IL1R signaling and provide a sensitive readout of exogenous LPS contamination. However, the inflammatory gene signature in tumors isolated from MyD88-deficient mice revealed few differences compared to controls for most MyD88-dependent genes (Figures S2B and S2C). The main differences observed in MyD88-deficient CD11b⁺ TAMs compared to controls were in mRNAs encoding members of the IL-12 family (IL-12b, IL-12a, IL-27, and IL-23) and G-CSF (Figure S2B).

Collectively, we concluded our isolation procedure caused minimal experimental-derived perturbation of inflammatory gene expression. In the absence of MyD88, inflammatory gene expression stayed intact with the exception of IL-12 family members, the opposite of the conclusions drawn from in vitro adenovirus-mediated IKK manipulation (Hagemann et al., 2008). The underlying reasons for the specificity of MyD88 signaling toward such a restricted set of mRNAs in our in vivo model remain to be established but are similar to the narrow effects of MyD88 disruption in humans (Alsina et al., 2014). Therefore, factors other than TLR or IL-1R signaling were responsible for regulating M1 gene expression in TAMs.

TAMs Express M1- and M2-Associated Genes

We used microarray profiling and qRT-PCR of CD11b⁺ TAMs to capture information on whether distinct tumor types influence global TAM gene expression. Regardless of their origin, we found high expression of M1-associated inflammatory genes in CD11b⁺ TAMs (Figures 1A and S2D). The inflammatory signature of the highest expressed genes was concordant between TAMs independent of tumor type, arguing mechanisms common to the tumor microenvironment were responsible for driving the inflammatory phenotype. Closer inspection of the CD11b⁺ TAM array data showed expression of numerous M2 signature mRNAs (Arg1, Mrc1, Chi3l3, Socs2, and Ccl24; Figure 1A). Furthermore, the CD11b⁺ TAM fraction was ARG1⁺ relative to separately purified tumor cells (Figure 1B). These data suggest both M1 and M2 gene expression signatures were simultaneously present within the CD11b⁺ TAM fraction. Given reports claiming TAMs are M2 (Biswas and Mantovani, 2010) or M1 (Franklin et al., 2014) or have more-complex phenotypes (Biswas et al., 2006; Colegio et al., 2014; Elpek et al., 2014; Chittechath et al., 2014; Murray et al., 2014), we next investigated the relationship between M1-M2 TAMs in more detail.




Figure 1. Cooperative MyD88-TNF Signaling Drives Expression of M1/M2 Genes in TAMs

(A) M1- and M2-associated gene expression in TAMs isolated from three tumor models (Glio, glioma; Neuro, neuroblastoma; Thymo, thymoma) and analyzed by microarray. Signal intensities are shown with the rank among 45,037 probe sets (in N-TAMs). Color code represents high (yellow) to low (blue) intensities. Data are representative of the log₂ signal intensities (n = 3 per TAM type).

(B) Immunoblot analysis of ARG1 expression in CD11b⁺ and CD11b⁻ fractions isolated from EG7 thymomas or gliomas grown in *Arg1*^{fllox/fllox};Tie2-cre (*Arg1*^{KO}) and WT (*Arg1*^{fllox/fllox} littermates) mice.

(C–E) qRT-PCR of EG7 TAM RNA isolated from WT, TNFR^{KO}, *Myd88*^{ΔH}, or DKO mice.

Each dot represents the expression values from individual mice from at least two experiments with the black line representing the mean. The error bars represent SEM. Statistical significance was calculated using two-tailed Student's t test and is indicated by *p < 0.05, **p < 0.01, and ***p < 0.001.

Type 1 TNFR Signaling Is a Central Negative Regulator of M2 TAMs

As discussed above, MyD88-deficient TAMs revealed few differences compared to controls for inflammatory genes (Figures S2B and S2C). Reasoning redundant inflammatory pathways might cooperate with MyD88 to promote the TAM signature, we focused on TNF because mRNAs encoding TNF, TNFR1 (TNFRp55, encoded by *Tnfrsf1a*), and TNFR2 (encoded by *Tnfrsf1b*) were highly expressed in TAMs based on our microarray data and TNF activates NF- κ B to drive inflammation, potentially overlapping with, or compensating for, the MyD88 pathway. We therefore used mice lacking TNFR1 (called TNFR^{KO}) as a source of TAMs. Coincident with these studies, we also generated mice in which type I TNF receptor, TLR, and IL-1R signaling were collectively ablated to generate a more-comprehensive view of potential signaling redundancies by NF- κ B-activating receptors. To do this, we used TNFR1 and *Myd88*^{ΔH} TNFR^{KO} double knockout mice (called DKO). The global MyD88 knockout has multiple effects in non-hematopoietic cells (Yu et al., 2014), and we therefore generated mice lacking MyD88 in the hematopoietic compartment (called *Myd88*^{ΔH}) using the Tie2-Cre deleter (El Kasmi et al., 2008). The macrophage/neutrophil-specific LysM-Cre deleter was also tested; however, the low degree of deletion of MyD88 protein in TAMs precluded the use of these mice in our experiments (Figure S2E).

TAMs lacking both MyD88 and TNFR1 showed substantial or complete reduction in most M1 inflammatory gene expression (Figure 1C) that correlated with a concomitant increase in tumor size (Figures S3A and S3B) that was intrinsic to macrophages as transplantation of tumors with BMDMs from control or TNFR^{KO} mice into CCR2-deficient animals (which lack the majority of TAMs) recapitulated the increases in tumor size (Figures S3C–S3E). TNF mRNA expression was reduced in DKO TAMs, suggesting the ablation of both MyD88 and TNFR signaling disrupted feedforward inflammatory loops driving M1 gene expression via TNF (Figure 1D). Thus, TLR/IL-1R and TNF signaling collectively enforced a cooperative pro-inflammatory pathway responsible for the M1-like TAM signature, and these data likely accounted for the limited phenotype of the MyD88-deficient mice; TNF signaling is redundant with TLR/IL-1R signaling in TAMs.

By contrast to the reduction in M1 gene expression in DKO mice, M2 gene expression in TAMs from TNFR^{KO}, DKO, and to a certain extent from *Myd88*^{ΔH} mice showed a remarkable signature (Figure 1E). TAMs isolated from DKO mice showed increased production of M2-associated mRNAs, suggesting that MyD88 and TNF signaling collectively masked or actively repressed M2 gene expression. In *Myd88*^{ΔH} TAMs, the TNF mRNA was among the strongest reduced transcripts. We therefore hypothesize the effects of MyD88 deletion in TAMs on M2-associated genes expression rely on reduced signaling downstream TNFR1 similar to TNFR^{KO} TAMs.

M2 Gene Expression Is Enriched in CD11b⁺, Ly6C⁻, MHCII⁺ TAMs from TNFR^{KO} Mice

An issue stemming from the above experiments concerned which cells in the tumor microenvironment were expressing the M2 markers. To address this, we noted many MyD88-dependent

genes in the CD11b⁺ fraction were enriched in the Ly6G⁺ neutrophil fraction (Figure S3F). These data prompted us to modify our TAM isolation procedure (Figures 2A and 2B) to more specifically isolate different TAM fractions (Kratochvill et al., 2015). We built upon methodologies (Movahedi et al., 2010; O'Sullivan et al., 2012) where the CD11b⁺ fraction was sub-divided into four populations: neutrophils (Ly6G⁺ and CD11b⁺), the TAMs directly descended from blood monocytes called TAM-A (CD11b⁺, Ly6C^{hi}, and MHCII⁻), TAM-B (CD11b⁺, Ly6C⁺, and MHCII⁺) and TAM-C (CD11b⁺, Ly6C⁻, and MHCII⁺). TAM-A, -B, and -C originated from monocytes because each of these cells was absent in *Ccr2*^{-/-} mice (Figure 2A) (Cortez-Retamozo et al., 2012; Franklin et al., 2014; Shand et al., 2014). Furthermore, results from tracing relationships between monocytes and their progeny suggests “mature” TAM-C are descended from TAM-A (Movahedi et al., 2010), in a process similar to other inflammatory models where local macrophages originate from blood monocytes seeding an inflammatory site (Bain and Mowat, 2014; Bain et al., 2013). Furthermore, the CD11b⁺ population contains cells consistent with their identity as eosinophils (Eos, discussed below) distinguished from monocytes by the degree of Ly6C expression (Figures 2A and 2B). Consistent with other data showing macrophage cell surface phenotypes change with maturation from monocytes (Movahedi et al., 2010; O'Sullivan et al., 2012), we found increased F4/80 and CX3CR1 expression on mature TAM-B and TAM-C relative to the monocyte-rich TAM-A fraction (Figure 2C).

Coincident with our flow cytometry protocol, we used orthotopic tumor models as a reproducible experimental standard that can be transplanted into any mouse on a C57BL/6 background (EG7, Lewis lung carcinoma, and B16 melanoma). When we compared the CD11b⁺ populations in each model, a gradient of non-monocytic Ly6C⁺ infiltration was observed. EG7 tumors had high numbers of non-monocytic Ly6C⁺ whereas B16 tumors were devoid of these cells (Figure 2D). As described later, this heterogeneity provided a platform to test the contribution of eosinophils to TAM polarization phenotypes. We therefore sorted the TAM-A and TAM-C fractions from EG7-bearing mice and subjected each fraction to microarray analysis. We found that the expression of nearly all M2 marker mRNAs were (1) enriched in the TAM-C fraction relative to TAM-A and (2) increased in the absence of type I TNFR signaling (Figure 2E). These data suggest TNF is an in vivo repressor of M2 signaling in TAMs.

TNF Blocks STAT6-Dependent M2 Gene Expression in a Gene-Specific Manner

Next, we asked whether TNF was a general inhibitor of M2 gene expression (Figure 3A). We generated bone-marrow-derived macrophages (BMDMs) with recombinant CSF-1 and stimulated them with IL-4 and IL-13 to induce M2 gene expression via STAT6, with or without recombinant TNF. We measured M2 gene expression by qRT-PCR and found three patterns (Figures 3A–3C). First, mRNAs encoding *Retnla* (also called *FIZZ1*), *Mgl2*, and *Mrc1* (mannose receptor) were induced by IL-4 and IL-13 as expected but repressed by TNF (Figure 3A). *Arg1* mRNA was also induced by IL-4 and IL-13 as expected, but not blocked by TNF (Figure 3B). The final group of mRNAs encoded the M2 chemokines *CCL17* and *CCL22*, which were induced by TNF,




Figure 2. MyD88 and TNFR1 Signaling Suppresses M2 Gene Expression in TAMs

(A) Gating strategy of TAM populations A (red ellipse), B (orange ellipse), and C (green ellipse) as well as tumor-infiltrating eosinophils (Eos, purple square) and double negative (DN) cells for sorting experiments comparing EG7 TAMs from WT and *Ccr2*^{-/-} mice.

(B) Schematic representation of TAM development from TAM-A to TAM-C.

(C) F4/80 and CX3CR1-GFP expression in EG7 TAMs isolated from WT and CX3CR1-GFP mice in TAM fractions as shown in (A) and (B). Data are representative histograms of three (F4/80; n = 10) or one (CX3CR1-GFP; n = 3) experiments.

(D) TAM fractions in macrophages gated as shown in (A) isolated from different transplantable tumor models. Blots are representative for at least two experiments where each experiment used at least five mice per tumor type.

(E) Transcriptome analysis of EG7 TAM populations A and C derived from WT, TNFR^{KO}, *Myd88*^{dH}, or DKO mice. Depicted values of M1- and M2-associated genes are heatmaps arranged by log₂ signal intensities (n = 2 per genotype).




Figure 3. TNF Signaling Blocks IL-13-Derived M2 Polarization

(A–C) qRT-PCR analysis of BMDMs left unstimulated or treated with a cocktail of IL-4 and IL-13 in combination with or without TNF for the times indicated. Data are the mean expression values ($n = 2$) and are representative for one out of two experiments.

(legend continued on next page)

but not by IL-4 and IL-13, the opposite phenotype to TAMs where expression of each mRNA is enhanced in the absence of TNFR1 signaling (Figures 1E and 2E). When viewed collectively, these data showed the negative effects of TNF on M2 gene expression we observed in the tumor microenvironment can only in part be translated to in vitro experiments using BMDMs. Importantly, TNF blocked M2 expression in a gene- and macrophage-type-specific way. The latter point prompted us to return to investigate in more detail the signaling events that established the M2 phenotype within the tumor microenvironment.

STAT6 Is Required for TAM M2 Gene Expression

Recent results showed lactate and hypoxia are important factors in amplifying M2-associated gene expression, especially *Arg1* (Colegio et al., 2014; El Kasmi et al., 2014). However, IL-4 and IL-13, via STAT6 phosphorylation, are widely accepted as the major drivers of M2 gene expression. We found TAM-A and TAM-C from EG7 TAMs expressed the IL-4R α and IL-13R α (Figure 3D) consistent with the ability of these cells to activate STAT6. We used the orthotopic transplant system in *Stat6*^{-/-} mice on a pure C57BL/6 background and generated TAM fractions. We found overall M2 gene expression for six targets and expression of PD-L2 (Huber et al., 2010) was reduced or eliminated in the absence of STAT6 (Figures 3E and 3F). However, these data also allowed us to test the STAT6-independent expression of individual genes. Consistent with recent data (Colegio et al., 2014), *Arg1* mRNA expression was partially affected by the loss of STAT6, indicating other pathways regulate *Arg1*, whereas mRNAs encoding *Retnla* and *Ccl24* were substantially reduced (Figure S4A). Importantly, the amounts of surface IL-4R α or IL-13R α were unaffected by genetic perturbation of the STAT6 or TNFR pathways (Figure 3G). These data are consistent with a model where multiple factors collaborate to provide an M2 permissive environment; lactate/hypoxia are likely one signal collaborating with STAT6 but work in a gene-specific way (Colegio et al., 2014; El Kasmi et al., 2014).

IL-13 Amplifies M2 TAMs and Is Blocked by TNF

Given our data showed an important contribution of IL-4- and IL-13-activated STAT6 to TAM M2 gene expression, we next asked whether we could detect IL-13 or IL-4 in the tumor environment. We found elevated amounts of IL-13 in bulk TAMs isolated from TNFR^{KO} mice, raising the possibility that IL-13 expression was suppressed by TLR and/or TNF signaling (Figure 4A). IL-4 and IL-13 are produced by many immune cells including T cells, ILCs, neutrophils, and even macrophages under certain conditions. Unlike recent findings showing neutrophils are a central

source of IL-13 in helminth infections (Chen et al., 2014), we could not detect IL-13 in tumor infiltrating Ly6G⁺ neutrophils (Figure 4B). Similarly, we found T cell numbers in orthotopic tumors were very low and unchanged in the TNFR^{KO} mice, suggesting T cells were not a major source of IL-13 in our models (Figures S4B–S4F). However, IL-13 mRNA expression was enriched in non-monocytic CD11b⁺ Ly6C⁺ cells from TNFR^{KO} mice with characteristics of eosinophils (Lee et al., 2012) (Figures 4B and 4C). The eosinophil-like cells expressed variable amounts of SiglecF and had the cytological appearance of eosinophils (Figures 4C and 4D). However, they did not express CCR3, an eosinophil and red pulp macrophage marker as defined by the ImmGen database, which may be downregulated in the tumor microenvironment. These cells are referred to hereafter as eosinophils. Neutralization of IL-13 with a monoclonal antibody (mAb) in EG7-bearing TNFR^{KO} mice showed partial reduction of M2 gene expression, consistent with the idea that local IL-13 is required in part to increase TAM M2 polarization (Figure 4E).

These data suggested TNF signaling negatively regulates two steps in the tumor microenvironment. First, TNF directly blocked specific sets of M2 genes. Second, TNF suppressed IL-13 expression from eosinophils and thus prevented production of a key M2-activating cytokine; the net effect was local reduction in M2 gene expression. If this model is valid, then we should be able to correlate eosinophil numbers in tumors with M2 gene expression. To test this prediction, we used the orthotopic transplant system where EG7, LLC, and B16 tumors were infiltrated with different amounts of eosinophils, such that EG7 had the most and B16 tumors the least (Figures 2D and 5A). Consistent with our model, the number of eosinophils correlated with the amount of IL-13 mRNA detected in the different tumor models in TNFR^{KO} mice (Figure 5B). When we analyzed gene expression in each tumor, a correlation in M2 expression from EG7 > LLC > B16 was observed in the TNFR-deficient mice (Figure 5C). These data therefore define, in an in vivo model system, that TNF signaling is a negative regulator of both IL-13 production and responsiveness of macrophages to IL-13.

Anti-TNF drugs have been successfully used for chronic inflammation for two decades. The mechanism of action of anti-TNF drugs is to block TNF, limiting feedforward inflammation. However, based on our data, a linked mechanism could be the promotion of M2 macrophages. To test this hypothesis in cancer, we used etanercept, a soluble TNFR that partially limits TNF bioavailability. Administration of etanercept to mice bearing EG7 tumors caused a relative increase in IL-13 as well as M2 gene expression in CD11b⁺ TAMs that did not reach the magnitude of the effect seen in the complete

(D) Flow histograms of IL-4R α and IL-13R α expression in EG7 TAM populations A and C, representative of two experiments (n = 10). Unstained control is shown in gray.

(E) qRT-PCR of M2 genes EG7 TAM populations A and C isolated from WT and *Stat6*^{KO} mice. Data are the expression values from individual mice (n \geq 7) from two experiments with the black line representing the mean.

(F) The expression of the M2 marker PD-L2 in EG7 TAM populations A and C was analyzed by flow cytometry isolated from WT and *Stat6*^{KO} mice. Data are shown as median fluorescence intensity (MFI) (n = 3) and representative flow analysis in TAM-C.

(G) IL-4R α and IL-13R α expression in EG7 TAM populations A and C analyzed by flow cytometry as shown in (D) isolated from WT, TNFR^{KO}, and *Stat6*^{KO} mice. Data are shown as MFI (WT; *Stat6*^{KO}: n = 4; TNFR^{KO}: n = 3) and represent one out of three experiments.

Statistical significance was calculated using a two-tailed Student's t test and is indicated by *p < 0.05, **p < 0.01, and ***p < 0.001. The error bars represent SEM.




Figure 4. Tumor-Infiltrating Eosinophil-Derived IL-13 Drives M2 Expression in TAMs

(A and B) qRT-PCR analysis of IL-13 production in EG7 TAM unsorted (A) or sorted for TAM subpopulations as depicted in Figures 2A and 2B. Values from individual mice (A: $n \geq 21$; B: $n \geq 10$) from at least two experiments are shown. Data in (B) were normalized to eosinophils (Eos). The error bars represent SEM.

(C) SiglecF expression analyzed by flow cytometry in TAM subpopulations gated as shown in Figure 2. Plots are representative for three experiments.

(D) H&E stained cytopsin slides of EG7 TAM populations (40 \times magnification). Pictures shown are representative of two experiments ($n = 4$).

(E) qRT-PCR analysis of CD11b⁺ EG7 TAMs derived from control IgG1 or anti-IL-13 antibody-treated TNFR^{KO} mice ($n \geq 5$). Mean expression values from one of two experiments are shown. The error bars represent SEM. Statistical significance was calculated using a one-way ANOVA (B) or two-tailed Student's t test (A and E) and is indicated by * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

DISCUSSION

Our experiments provide a conceptual framework for explaining why both M1 and M2 TAMs have been observed in cancer: the quantity of macrophages at either end of the polarization spectrum depends on the balance between IL-13 (and possibly IL-4) delivery by eosinophils and the overall amount of TLR, IL-1R, and TNFR signaling. Therefore, we predict cancers associated with high amounts of endogenous commensal- and pathogen-derived molecules, DAMPs, and TNF such as colon cancer will trend to the M1 end of the spectrum because the STAT6-dependent M2 response will be suppressed. Conversely, we predict tumors with low relative inflammation such as at sterile sites like breast and head and neck tumors or developmental tumors of childhood will have higher relative numbers of M2 macrophages because the TNF: M2 balance shifts in

TNFR^{KO} mice as expected based on previous experiments comparing etanercept and potent antibody-based TNF blockers (Vos et al., 2012) (Figures 6A and 6B). Consistent with data showing Arg1 gene expression is regulated by via multiple pathways, Arg1 mRNA was not increased by etanercept treatment (Figure 6C). Therefore, TNF inhibition is linked to the promotion of M2 macrophages, which may contribute to the salutary effects of anti-TNF drugs in colitis and rheumatoid arthritis but may also promote a tumor-permissive M2 environment in cancer.

favor of M2 TAMs. This balance is likely further controlled by temporal and spatial variables within the microenvironment.

The key finding of our work is that TNF negatively regulates M2 gene expression both in vivo and in vitro. We established TNF did not inhibit all M2 gene expression. Instead, TNF targeted subsets of genes. These data argue for a model where downstream signals from the type I TNFR, such as NF- κ B, act in a gene-specific way. Our data can be used to explain phenotypes of knockout mice where unanticipated polarization switching was observed but could be correlated with local TNF




Figure 5. M2 Gene Expression in TNFR^{KO} TAMs Correlates with Tumor-Infiltrating Eosinophils

(A) Frequency of tumor-infiltrating eosinophils in three different tumor models (EG7, LLC, and B16) in WT and TNFR^{KO} mice gated as in Figure 2A. Data are values from individual mice ($n \geq 6$) from at least two independent experiments per tumor model. Cell frequencies are shown as percent Ly6C⁺/MHCII⁻ cells of all CD11b⁺Ly6G⁻ cells. The error bars represent SEM.

(B and C) qRT-PCR analysis of CD11b⁺ TAMs isolated from different tumor models in WT and TNFR^{KO} mice as in (A) ($n \geq 5$).

Data are the mean expression values normalized to the corresponding WT TAMs in each tumor model and represent values from individual mice from at least two independent experiments per tumor model. The error bars represent SEM.

production. For example, CD14-deficient mice have greatly enhanced M2-driven granulomatous response to schistosome eggs trapped in the liver. In these granulomas, macrophages express high amounts of M2 genes Retnla, Arg1, and Chi3l3 expression relative to controls (Tundup et al., 2014). One explanation for the phenotype is loss of CD14, an essential surface component of TLR signaling, will lead to defects in local TNF production and enhanced M2 responses. Another example of chronic inflammation linked to the inverse balance between TNF and M2 macrophages is obesity. In lean adipose tissue, M2-like tissue resident macrophages interdigitate between fat cells, whereas in obesity, excess fat suppresses M2 macrophages and is associated with increased TNF (Lumeng et al., 2007; Weisberg et al., 2003; Xu et al., 2003).

However, when TLR4 signaling is genetically ablated in obesity, M2-associated macrophage genes increase, and this phenotype paralleled a decline in TNF (Orr et al., 2012). Therefore, a general prediction from our studies is many inflammation-linked polarization phenotypes might be dictated by an inverse relationship between TNF and signals driving M2 polarization (IL-4 and IL-13); increased TNF will block M2 polarization in a gene-specific way, depending on quantity, time, and spatial availability. The conceptual advance made here to inversely link M2 polarization and TNF may also help explain why cytotoxic therapy is linked to M1 macrophages as the necrotic and apoptotic death of large numbers of tumor cells releases DAMPs (Klug et al., 2013), which through local TNF generation, will suppress IL-13 and IL-4 from eosinophils and thus also suppress STAT6-dependent M2 TAMs. Finally, we suggest anti-TNF drugs might also work through the combined effects of suppressing a pro-inflammatory signal that concomitantly causes a rise in M2 macrophages. Indeed, anti-TNF drugs promote changes in macrophage phenotype, and this effect is proportional to TNF neutralization (Vos et al., 2011, 2012). We used etanercept, a soluble TNFR, which was noted to have the weakest effect of macrophage phenotypic changes. Our in vivo data confirmed this finding, as etanercept caused increases in TAM M2 gene expression, which were less than that observed in the complete TNFR1-deficient mice. Therefore, we consider an important direction stemming from our work will be to reconsider the mechanistic actions of TNF blockers. For example, anti-TNF therapy causes tuberculosis reactivation, a phenotype attributed to removal of TNF (Flynn et al., 1995). However, because M2 macrophages are permissive to TB (Potian et al., 2011), we predict part of the reason anti-TNF drugs are contraindicated for TB-infected patients is linked to elevations of M2 macrophages.

A previous study using an ovarian cancer model claimed NF- κ B signaling was required for maintaining the expression of M2 genes (Hagemann et al., 2008). These results are difficult to interpret for several reasons. NF- κ B signaling is necessary for most inflammatory gene expression. In Hagemann et al. (2008), inhibition of NF- κ B by manipulating IKK β caused increases in IL-12p40 and iNOS expression, the opposite of what one would expect, as expression of both genes requires contributions from NF- κ B complexes for optimal expression (Farlik et al., 2010; Sanjabi et al., 2000; Sen and Smale, 2010; Zhou et al., 2004). In our in vivo studies, IL-12p40 expression is dependent on MyD88 in TAMs residing in the tumor microenvironment, arguing for a positive role of NF- κ B activation downstream of TLR signaling. The conclusions drawn by Hagemann et al. derived from an experimental system where adenoviruses were used to transfer dominant-negative versions of IKK β or Cre recombinase into CSF-1-generated BMDMs. As the effects of viral infection in the absence of functional NF- κ B signaling in the experimental arms were unaccounted for, the claims of this study remain difficult to interpret and differ from most other findings in the field.

Our data clearly show eosinophil-derived IL-13 is one factor provoking M2 polarization. Therefore, local IL-13 will enhance M2 polarization, depending on how much TNF is present. IL-4 may also be a key factor in TAM M2 polarization, but we found




Figure 6. Treatment with the Anti-TNF Drug Etanercept Enhances IL-13 and M2-Associated Gene Expression in TAMs

qRT-PCR analysis of CD11b⁺ EG7 TAMs isolated from PBS- (n ≥ 17) or etanercept- (n ≥ 18) treated WT mice compared to TAMs from TNFR^{KO} mice (n ≥ 11). Data represent individual mice from three experiments normalized to the corresponding mean PBS-treated WT TAMs per experiment. The error bars represent SEM. Statistical significance was calculated using a two-tailed Student's t test and is indicated by *p < 0.05, **p < 0.01, and ***p < 0.001.

IL-4 expression difficult to reliably detect, consistent with observations made in other systems and with different IL-4 reporter mice (Liang et al., 2012). Our data are consistent with recent studies in helminth infections showing neutrophils are the source of M2-enhancing cytokines and that eosinophils produce IL-4 and IL-13 in beige fat-associated macrophages (Chen et al., 2014; Qiu et al., 2014). One unexpected facet of our data was the inhibitory effect of TNF on IL-13 production from eosinophils, as the loss of type I TNF signaling greatly enhanced eosinophil IL-13 production. Therefore, an eosinophil-intrinsic signaling pathway from the TNFR blocks IL-13. Indeed, a recent study has shown eosinophils have potent anti-tumor properties when activated and co-transferred with cytotoxic T cells (Carretero et al., 2015). In this study, the eosinophils were pre-treated with TNF and IFN- γ and co-transferred with activated OT1 T cells, which can make TNF. Therefore, understanding the balance of signals that control TNF, IL-13, eosinophils, and TAMs may be important in understanding and modulating inflammation in addition to the potential for rational manipulation of macrophage polarization in the tumor microenvironment.

EXPERIMENTAL PROCEDURES

Mice

C57Bl/6, *Myd88*^{flox/flox}, *Stat6*^{-/-}, B6.Cg-*Tg(Tek-cre)*^{1Ywa} (Tie2-Cre), *Ccr2*^{-/-}, *Cx3cr1*^{GFP}, and *Lyz2*^{tm1(cre)flw}/J (LysM-Cre) mice were obtained from Jackson Laboratories. TNFR1 knockout mice (*Tnfrsf1a*^{-/-}) were a gift from V. Redecke (St. Jude Children's Research Hospital). *Myd88*^{-/-} mice were obtained from D. Green (St. Jude Children's Research Hospital) and were originally a gift from S. Akira (Osaka University). *Arg1*^{flox/flox} mice have been described elsewhere and were crossed to Tie2-Cre mice (El Kasmi et al., 2008). Littermate controls that were Cre negative or positive were used. The above-mentioned mouse lines were crossed to a pure C57Bl/6 background (greater than ten generations) in house or as supplied from Jackson Laboratories. C57Bl/6 control animals were bred and housed in the same rooms at St. Jude Children's Research Hospital. Where intercrossing was performed, littermate controls were used where feasible. All mouse breeding, husbandry, and tumor models

were performed according to established guidelines for laboratory animal use. Th-MYCN transgenic (Weiss et al., 1997), *Chx10-Cre*, *Rb*^{flox/flox}, *p107*^{-/-}, *p130*^{flox/flox}, and *Mdmx-tg*; *Rb*^{flox/flox}; *p107*^{-/-}; *Chx10-Cre* mice were used as sources of retinoblastomas, and *Rb*^{flox/flox}; *p53*^{flox/flox}; *Osx-Cre*⁺ mice were used to generate osteosarcomas. All mice used in this study were co-housed by sex and were bred and used within the Animal Resource Center according to protocols approved by the IACUC at St. Jude Children's Research Hospital.

Tumor Models—In Vivo

Glioma

Gliomas were engineered from granule neural progenitors purified from cerebella of *Tp53*^{-/-}, *Cdkn2c*^{-/-}, *Math1-GFP* 5- to 7-day-old pups, transduced with retroviruses expressing an HER2/Neu mutant ERBB2 V695A and the red fluorescent protein dsRed (MSCV-ERBB2V695A-IRES-dsRed). 1 × 10³ GFP-RFP double-positive cells were implanted in the cortices of CD1 nude mice (Kawauchi et al., 2012) for 69–77 days. 3 × 10⁶ tumor cells from dissociated gliomas were injected subcutaneously into the flank of recipient C57Bl/6 mice for TAM isolation.

Thymoma

EG7 lymphoma line originating from the thymus (EL4, stably expressing OVA protein) was injected subcutaneously into the flank of recipient mice (3 × 10⁶ cells/mouse). Gliomas and thymomas were harvested from mice between 1.5 and 2 weeks post-transplant.

Neuroblastoma

Spontaneous neuroblastomas detected by ultrasound were collected from the peritoneum of Th-MYCN transgenic (tg) mice.

Retinoblastoma

Spontaneous retinoblastomas were collected behind the eye from either *Rb*^{flox/flox}; *p107*^{-/-}; *Chx10-Cre* or *MDMX-tg*; *Rb*^{flox/flox}; *p107*^{-/-}; *Chx10-Cre* mice.

Osteosarcoma

Spontaneous osteosarcomas were collected from *Rb*^{flox/flox}; *p53*^{flox/flox}; *Osx-Cre*⁺ mice. LLC and B16 tumor models were used as described (Haverkamp et al., 2014).

Media and Reagents

Tumor Digestion Media

Tumor digestion media (TDM) was 5 mg DNase I (Worthington), 12.5 mg collagenase P (Roche), 12.5 mg collagenase/dispase (Roche), 100 μ l B27 (Invitrogen), and 50 μ l N2 (Invitrogen), made to 5 ml with Neural Basal medium (Invitrogen), followed by 0.22 μ m filter sterilization.

DNase Solution

DNase solution (DS) was 7.5 mg DNase I (Worthington) and 120 μ l 45% glucose solution (Sigma-Aldrich), up to 15 ml with 1× Basal Medium Eagle media (Invitrogen), followed by 0.22 μ m filter sterilization.

Percoll Solution

Percoll (Sigma-Aldrich) was adjusted to a final pH of 7.4 followed by 0.22 μ m filter sterilization. 35% percoll (25 ml 4 \times PBS-EDTA, 35 ml percoll, and 40 ml water) and 60% percoll (25 ml 4 \times PBS-EDTA, 60 ml percoll, 15 ml water, and 300 μ l 0.4% trypan blue; Invitrogen) stocks were prepared and stored at 4°C.

Cytokines

IL-4, TNF, IFN- γ (all eBioscience), IL-13 (Peprotech), and LPS (Sigma-Aldrich) were used at 10 ng/ml, 10 ng/ml, 2 ng/ml, 40 ng/ml, or 100 ng/ml, respectively. Anti-mouse IL-13 antibody and IgG1 control (clone MOPC-21) were provided by Genentech and Bio X Cell, respectively.

TAM Isolation

Solid tumors were excised and minced using a scalpel. Five milliliters of fresh TDM was added, transferred to a 50-ml conical tube, and incubated for 20 min shaking at 37°C. Tumor fragments were dissociated with a 10-ml pipet and passed through a 70- μ m strainer. To collect loosely attached cells, the strainer was then washed with 10 ml PBS. Tumor cells were centrifuged for 5 min at 300 g, 4°C, and the supernatant was aspirated. Cells were resuspended in 1 ml fresh DS. Following resuspension, 4 ml PBS was added and cells were overlaid on a 35%/60% percoll gradient. Percoll gradients with cells were centrifuged for 20 min at 2,000 g, 4°C, with the brakes disengaged. Tumor cells and macrophages were collected from the 35%/60% interphase, transferred to a 50-ml conical tube containing 10 ml PBS, and centrifuged for 5 min at 300 g, 4°C. For RNA preparation of TAMs or TAM populations after cell sorting, cells were resuspended in MACS buffer with 10% normal mouse serum for blocking and TAMs were collected by CD11b purification using Miltenyi magnetic beads. CD11b⁺ and CD11b⁻ fractions were analyzed by flow cytometry and/or cytospin.

Flow Cytometry

Cells were resuspended in 200 μ l FACS buffer (PBS with 5% bovine calf serum) and placed on ice for 15 min to block. Cells were incubated with fluorescently labeled antibodies on ice in the dark for 20 min and then washed with PBS, centrifuged at 500 \times g for 5 min, resuspended in 200 μ l FACS buffer, and evaluated on a FACSCanto (Becton Dickinson) flow cytometer. Cell death was determined using an Annexin V Apoptosis Detection Kit I (BD Pharmingen). Data were further analyzed using FlowJo software (Tree Star).

RNA Isolation and qRT-PCR Analysis

RNA was collected from TAMs and other cells using Trizol (Invitrogen), according to the manufacturer's protocol. cDNA was synthesized using SuperScript II reverse transcriptase (Invitrogen) and analyzed by qRT-PCR using the primer pairs listed in [Supplemental Information](#). All values were normalized to GAPDH.

Anti-IL-13 Antibody Treatment

Two hundred micrograms anti-IL-13 antibody or IgG1 control were injected i.v. per mouse bearing EG7 thymomas 6 days before tumor harvest.

Etanercept Treatment

EG7 tumor-bearing mice received a daily dose of 0.060 mg/mouse etanercept (Enbrel) or PBS as control by subcutaneous injection starting 5 days after implantation of the EG7 cells until tumor harvest on day 11.

Statistics

Data indicate the mean \pm SEM of representative experiments. Statistical significance was determined by a two-tailed Student's *t* test or one-way ANOVA followed by Bonferroni post test where indicated in the figure legends using Graphpad Prism5 justified according to the normality and variance of the distribution (**p* < 0.05; ***p* < 0.01; ****p* < 0.001). Sample size for adequate power was estimated using preliminary studies.

ACCESSION NUMBERS

The accession numbers for the microarray data reported in this paper are GEO: GSE59047 and GEO: GSE68817.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures and four figures and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2015.08.033>.

AUTHOR CONTRIBUTIONS

F.K., J.E.Q., and P.J.M. conceived the project and experimental design. F.K. and J.E.Q. did most of the experiments. G.N. did the bioinformatics analysis. L.-A.V.d.V. and A.M.S. performed key experiments to establish the tumor models and helped maintain the mouse colony. J.M.H. performed experiments. D.K., J.M., M.F.R., and M.A.D. contributed key genetic tumor models, reagents, and advice. P.J.M., F.K., and J.E.Q. wrote the manuscript. All authors reviewed the manuscript.

ACKNOWLEDGMENTS

We thank Melissa Johnson and Chris Calabrese for animal imaging, Genentech and Lawren Wu for the gift of anti-IL-13 antibodies, and Richard Gilbertson for the gift of the ERBB2 V695A mutant plasmid. This work was supported by NIH grants CA189990 (to P.J.M.), CA096832 (to M.F.R.), and CA138064 (to J.E.Q.); by Alex's Lemonade Stand Foundation and the Hartwell Foundation (to P.J.M.); Cancer Center Core Grant P30 CA21765 (to P.J.M. and M.F.R.); the Austrian Science Fund J3309-B19 (to F.K.); the Anderson Fellowship (to D.K.); and the American Lebanese Syrian Associated Charities of St. Jude Children's Research Hospital.

Received: December 20, 2014

Revised: July 23, 2015

Accepted: August 7, 2015

Published: September 10, 2015

REFERENCES

- Ahn, G.O., Tseng, D., Liao, C.H., Dorie, M.J., Czechowicz, A., and Brown, J.M. (2010). Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. *Proc. Natl. Acad. Sci. USA* *107*, 8363–8368.
- Alsina, L., Israelsson, E., Altman, M.C., Dang, K.K., Ghandil, P., Israel, L., von Bernuth, H., Baldwin, N., Qin, H., Jin, Z., et al. (2014). A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4. *Nat. Immunol.* *15*, 1134–1142.
- Bain, C.C., and Mowat, A.M. (2014). Macrophages in intestinal homeostasis and inflammation. *Immunol. Rev.* *260*, 102–117.
- Bain, C.C., Scott, C.L., Uronen-Hansson, H., Gudjonsson, S., Jansson, O., Grip, O., Williams, M., Malissen, B., Agace, W.W., and Mowat, A.M. (2013). Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. *Mucosal Immunol.* *6*, 498–510.
- Bissell, M.J., and Hines, W.C. (2011). Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. *Nat. Med.* *17*, 320–329.
- Biswas, S.K., and Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat. Immunol.* *11*, 889–896.
- Biswas, S.K., Gangi, L., Paul, S., Schioppa, T., Saccani, A., Sironi, M., Bottazzi, B., Doni, A., Vincenzo, B., Pasqualini, F., et al. (2006). A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF- κ B and enhanced IRF-3/STAT1 activation). *Blood* *107*, 2112–2122.
- Bonapace, L., Coissieux, M.M., Wyckoff, J., Mertz, K.D., Varga, Z., Junt, T., and Bentires-Alj, M. (2014). Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. *Nature* *515*, 130–133.

- Carretero, R., Sektioglu, I.M., Garbi, N., Salgado, O.C., Beckhove, P., and Hämmerling, G.J. (2015). Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. *Nat. Immunol.* **16**, 609–617.
- Chen, F., Wu, W., Millman, A., Craft, J.F., Chen, E., Patel, N., Boucher, J.L., Urban, J.F., Jr., Kim, C.C., and Gause, W.C. (2014). Neutrophils prime a long-lived effector macrophage phenotype that mediates accelerated helminth expulsion. *Nat. Immunol.* **15**, 938–946.
- Chittezhath, M., Dhillon, M.K., Lim, J.Y., Laoui, D., Shalova, I.N., Teo, Y.L., Chen, J., Kamaraj, R., Raman, L., Lum, J., et al. (2014). Molecular profiling reveals a tumor-promoting phenotype of monocytes and macrophages in human cancer progression. *Immunity* **41**, 815–829.
- Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., Cyrus, N., Brokowski, C.E., Eisenbarth, S.C., Phillips, G.M., et al. (2014). Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. *Nature* **513**, 559–563.
- Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P.J., Chudnovskiy, A., Berger, C., Ryan, R.J., Iwamoto, Y., Marinelli, B., Gorbato, R., et al. (2012). Origins of tumor-associated macrophages and neutrophils. *Proc. Natl. Acad. Sci. USA* **109**, 2491–2496.
- Dannenmann, S.R., Thielicke, J., Stöckli, M., Matter, C., von Boehmer, L., Cecconi, V., Hermanns, T., Hefermehl, L., Schraml, P., Moch, H., et al. (2013). Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma. *Oncol Immunology* **2**, e23562.
- De Palma, M., and Lewis, C.E. (2013). Macrophage regulation of tumor responses to anticancer therapies. *Cancer Cell* **23**, 277–286.
- Dvorak, H.F. (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. *N. Engl. J. Med.* **315**, 1650–1659.
- El Kasmi, K.C., Qualls, J.E., Pesce, J.T., Smith, A.M., Thompson, R.W., Henaot-Tamayo, M., Basaraba, R.J., König, T., Schleicher, U., Koo, M.S., et al. (2008). Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. *Nat. Immunol.* **9**, 1399–1406.
- El Kasmi, K.C., Pugliese, S.C., Riddle, S.R., Poth, J.M., Anderson, A.L., Frid, M.G., Li, M., Pullamsetti, S.S., Savai, R., Nagel, M.A., et al. (2014). Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. *J. Immunol.* **193**, 597–609.
- Elpek, K.G., Cremasco, V., Shen, H., Harvey, C.J., Wucherpfennig, K.W., Goldstein, D.R., Monach, P.A., and Turley, S.J. (2014). The tumor microenvironment shapes lineage, transcriptional, and functional diversity of infiltrating myeloid cells. *Cancer Immunol. Res.* **2**, 655–667.
- Epelman, S., Lavine, K.J., and Randolph, G.J. (2014). Origin and functions of tissue macrophages. *Immunity* **41**, 21–35.
- Farlik, M., Reutterer, B., Schindler, C., Greten, F., Vogl, C., Müller, M., and Decker, T. (2010). Nonconventional initiation complex assembly by STAT and NF-kappaB transcription factors regulates nitric oxide synthase expression. *Immunity* **33**, 25–34.
- Flynn, J.L., Goldstein, M.M., Chan, J., Triebold, K.J., Pfeffer, K., Lowenstein, C.J., Schreiber, R., Mak, T.W., and Bloom, B.R. (1995). Tumor necrosis factor-alpha is required in the protective immune response against *Mycobacterium tuberculosis* in mice. *Immunity* **2**, 561–572.
- Franklin, R.A., Liao, W., Sarkar, A., Kim, M.V., Bivona, M.R., Liu, K., Pamer, E.G., and Li, M.O. (2014). The cellular and molecular origin of tumor-associated macrophages. *Science* **344**, 921–925.
- Fridman, W.H., Pagès, F., Sautès-Fridman, C., and Galon, J. (2012). The immune contexture in human tumours: impact on clinical outcome. *Nat. Rev. Cancer* **12**, 298–306.
- Gajewski, T.F., Schreiber, H., and Fu, Y.X. (2013). Innate and adaptive immune cells in the tumor microenvironment. *Nat. Immunol.* **14**, 1014–1022.
- Galon, J., Angell, H.K., Bedognetti, D., and Marincola, F.M. (2013). The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. *Immunity* **39**, 11–26.
- Hagemann, T., Lawrence, T., McNeish, I., Charles, K.A., Kulbe, H., Thompson, R.G., Robinson, S.C., and Balkwill, F.R. (2008). “Re-educating” tumor-associated macrophages by targeting NF-kappaB. *J. Exp. Med.* **205**, 1261–1268.
- Hanahan, D., and Coussens, L.M. (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. *Cancer Cell* **21**, 309–322.
- Haverkamp, J.M., Smith, A.M., Weinlich, R., Dillon, C.P., Qualls, J.E., Neale, G., Koss, B., Kim, Y., Bronte, V., Herold, M.J., et al. (2014). Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. *Immunity* **41**, 947–959.
- Huber, S., Hoffmann, R., Muskens, F., and Voehringer, D. (2010). Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. *Blood* **116**, 3311–3320.
- Kawauchi, D., Robinson, G., Uziel, T., Gibson, P., Rehg, J., Gao, C., Finkelshtein, D., Qu, C., Pounds, S., Ellison, D.W., et al. (2012). A mouse model of the most aggressive subgroup of human medulloblastoma. *Cancer Cell* **21**, 168–180.
- Klug, F., Prakash, H., Huber, P.E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R.H., Timke, C., Umansky, L., et al. (2013). Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. *Cancer Cell* **24**, 589–602.
- Kratochvill, F., Gratz, N., Qualls, J.E., Van De Velde, L.A., Chi, H., Kovarik, P., and Murray, P.J. (2015). Tristetraprolin limits inflammatory cytokine production in tumor-associated macrophages in an mRNA decay-independent manner. *Cancer Res.* **75**, 3054–3064.
- Lee, J.J., Jacobsen, E.A., Ochkur, S.I., McGarry, M.P., Condjella, R.M., Doyle, A.D., Luo, H., Zellner, K.R., Protheroe, C.A., Willetts, L., et al. (2012). Human versus mouse eosinophils: “that which we call an eosinophil, by any other name would stain as red”. *J. Allergy Clin. Immunol.* **130**, 572–584.
- Liang, H.E., Reinhardt, R.L., Bando, J.K., Sullivan, B.M., Ho, I.C., and Locksley, R.M. (2012). Divergent expression patterns of IL-4 and IL-13 define unique functions in allergic immunity. *Nat. Immunol.* **13**, 58–66.
- Lumeng, C.N., Bodzin, J.L., and Saltiel, A.R. (2007). Obesity induces a phenotypic switch in adipose tissue macrophage polarization. *J. Clin. Invest.* **117**, 175–184.
- Ma, Y., Adjemian, S., Mattarollo, S.R., Yamazaki, T., Aymeric, L., Yang, H., Portela Catani, J.P., Hannani, D., Duret, H., Steegh, K., et al. (2013). Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. *Immunity* **38**, 729–741.
- Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In’t Veld, P., De Baetselier, P., and Van Ginnecher, J.A. (2010). Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Res.* **70**, 5728–5739.
- Murray, P.J., and Wynn, T.A. (2011a). Obstacles and opportunities for understanding macrophage polarization. *J. Leukoc. Biol.* **89**, 557–563.
- Murray, P.J., and Wynn, T.A. (2011b). Protective and pathogenic functions of macrophage subsets. *Nat. Rev. Immunol.* **11**, 723–737.
- Murray, P.J., Allen, J.E., Biswas, S.K., Fisher, E.A., Gilroy, D.W., Goerdt, S., Gordon, S., Hamilton, J.A., Ivashkiv, L.B., Lawrence, T., et al. (2014). Macrophage activation and polarization: nomenclature and experimental guidelines. *Immunity* **41**, 14–20.
- Nakasone, E.S., Askautrud, H.A., Kees, T., Park, J.H., Plaks, V., Ewald, A.J., Fein, M., Rasch, M.G., Tan, Y.X., Qiu, J., et al. (2012). Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. *Cancer Cell* **21**, 488–503.
- Nathan, C., and Ding, A. (2010). Nonresolving inflammation. *Cell* **140**, 871–882.
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C.M., Arthur, C., White, J.M., Uppaluri, R., Andrews, D.M., Ngiow, S.F., Teng, M.W., et al. (2012). Cancer immunoeediting by the innate immune system in the absence of adaptive immunity. *J. Exp. Med.* **209**, 1869–1882.

- Orr, J.S., Puglisi, M.J., Ellacott, K.L., Lumeng, C.N., Wasserman, D.H., and Hasty, A.H. (2012). Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. *Diabetes* *61*, 2718–2727.
- Potian, J.A., Rafi, W., Bhatt, K., McBride, A., Gause, W.C., and Salgame, P. (2011). Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. *J. Exp. Med.* *208*, 1863–1874.
- Predina, J., Eruslanov, E., Judy, B., Kapoor, V., Cheng, G., Wang, L.C., Sun, J., Moon, E.K., Fridlender, Z.G., Albelda, S., and Singhal, S. (2013). Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. *Proc. Natl. Acad. Sci. USA* *110*, E415–E424.
- Pyonteck, S.M., Akkari, L., Schuhmacher, A.J., Bowman, R.L., Sevenich, L., Quail, D.F., Olson, O.C., Quick, M.L., Huse, J.T., Teijeiro, V., et al. (2013). CSF-1R inhibition alters macrophage polarization and blocks glioma progression. *Nat. Med.* *19*, 1264–1272.
- Qian, B.Z., and Pollard, J.W. (2010). Macrophage diversity enhances tumor progression and metastasis. *Cell* *141*, 39–51.
- Qiu, Y., Nguyen, K.D., Odegaard, J.I., Cui, X., Tian, X., Locksley, R.M., Palmiter, R.D., and Chawla, A. (2014). Eosinophils and type 2 cytokine signaling in macrophages orchestrate development of functional beige fat. *Cell* *157*, 1292–1308.
- Ries, C.H., Cannarile, M.A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L.P., Feuerhake, F., Klamann, I., et al. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. *Cancer Cell* *25*, 846–859.
- Ruffell, B., Affara, N.I., and Coussens, L.M. (2012). Differential macrophage programming in the tumor microenvironment. *Trends Immunol.* *33*, 119–126.
- Sanjabi, S., Hoffmann, A., Liou, H.C., Baltimore, D., and Smale, S.T. (2000). Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. *Proc. Natl. Acad. Sci. USA* *97*, 12705–12710.
- Sen, R., and Smale, S.T. (2010). Selectivity of the NF- κ B response. *Cold Spring Harb. Perspect. Biol.* *2*, a000257.
- Shand, F.H., Ueha, S., Otsuji, M., Koid, S.S., Shichino, S., Tsukui, T., Kosugi-Kanaya, M., Abe, J., Tomura, M., Ziogas, J., and Matsushima, K. (2014). Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. *Proc. Natl. Acad. Sci. USA* *111*, 7771–7776.
- Tundup, S., Srivastava, L., Nagy, T., and Harn, D. (2014). CD14 influences host immune responses and alternative activation of macrophages during *Schistosoma mansoni* infection. *Infect. Immun.* *82*, 3240–3251.
- Vos, A.C., Wildenberg, M.E., Duijvestein, M., Verhaar, A.P., van den Brink, G.R., and Hommes, D.W. (2011). Anti-tumor necrosis factor- α antibodies induce regulatory macrophages in an Fc region-dependent manner. *Gastroenterology* *140*, 221–230.
- Vos, A.C., Wildenberg, M.E., Arijis, I., Duijvestein, M., Verhaar, A.P., de Hertogh, G., Vermeire, S., Rutgeerts, P., van den Brink, G.R., and Hommes, D.W. (2012). Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro. *Inflamm. Bowel Dis.* *18*, 401–408.
- Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., and Ferrante, A.W., Jr. (2003). Obesity is associated with macrophage accumulation in adipose tissue. *J. Clin. Invest.* *112*, 1796–1808.
- Weiss, W.A., Aldape, K., Mohapatra, G., Feuerstein, B.G., and Bishop, J.M. (1997). Targeted expression of MYCN causes neuroblastoma in transgenic mice. *EMBO J.* *16*, 2985–2995.
- Wynn, T.A., Chawla, A., and Pollard, J.W. (2013). Macrophage biology in development, homeostasis and disease. *Nature* *496*, 445–455.
- Xu, H., Barnes, G.T., Yang, Q., Tan, G., Yang, D., Chou, C.J., Sole, J., Nichols, A., Ross, J.S., Tartaglia, L.A., and Chen, H. (2003). Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. *J. Clin. Invest.* *112*, 1821–1830.
- Yu, M., Zhou, H., Zhao, J., Xiao, N., Roychowdhury, S., Schmitt, D., Hu, B., Ransohoff, R.M., Harding, C.V., Hise, A.G., et al. (2014). MyD88-dependent interplay between myeloid and endothelial cells in the initiation and progression of obesity-associated inflammatory diseases. *J. Exp. Med.* *211*, 887–907.
- Zhang, Q.W., Liu, L., Gong, C.Y., Shi, H.S., Zeng, Y.H., Wang, X.Z., Zhao, Y.W., and Wei, Y.Q. (2012). Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. *PLoS ONE* *7*, e50946.
- Zhou, L., Nazarian, A.A., and Smale, S.T. (2004). Interleukin-10 inhibits interleukin-12 p40 gene transcription by targeting a late event in the activation pathway. *Mol. Cell. Biol.* *24*, 2385–2396.